Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) Income from Continuing Operations (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Income from Continuing Operations readings, the most recent being 39619000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 21.09% to 39619000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 149905000.0 through Mar 2026, down 2.24% year-over-year, with the annual reading at 143004000.0 for FY2025, 0.08% changed from the prior year.
  • Income from Continuing Operations hit 39619000.0 in Q1 2026 for Oric Pharmaceuticals, down from 34551000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 20696000.0 in Q2 2022 and bottomed at 39619000.0 in Q1 2026.
  • Average Income from Continuing Operations over 5 years is 30880058.82, with a median of 31428000.0 recorded in 2023.
  • The largest annual shift saw Income from Continuing Operations tumbled 50.76% in 2023 before it grew 12.68% in 2025.
  • Oric Pharmaceuticals' Income from Continuing Operations stood at 20847000.0 in 2022, then tumbled by 50.76% to 31428000.0 in 2023, then dropped by 25.91% to 39570000.0 in 2024, then increased by 12.68% to 34551000.0 in 2025, then dropped by 14.67% to 39619000.0 in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Income from Continuing Operations are 39619000.0 (Q1 2026), 34551000.0 (Q4 2025), and 36671000.0 (Q3 2025).